Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19

Elham Zendedel; Lobat Tayebi; Mohammad Nikbakht; Elham Hasanzadeh; Shiva Asadpour

doi:10.2174/011574888X260032230925052240

Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19

Curr Stem Cell Res Ther. 2023 Oct 5. doi: 10.2174/011574888X260032230925052240. Online ahead of print.

Authors

Elham Zendedel¹, Lobat Tayebi², Mohammad Nikbakht³, Elham Hasanzadeh⁴, Shiva Asadpour¹

Affiliations

¹ Shahrekord University of Medical Sciences Tissue Engineering and Applied Cell Sciences Shahr-e Kord Iran.
² Shahrekord University of Medical Sciences Dentistry Shahr-e Kord Iran.
³ Shahrekord University of Medical Sciences Medical Biotechnology Shahr-e Kord Iran.
⁴ Mazandaran University of Medical Sciences Tissue Engineering & Regenerative Medicine Sari Iran.

PMID: 37815188
DOI: 10.2174/011574888X260032230925052240

Abstract

Mesenchymal Stem Cells (MSCs) are being investigated as a treatment for a novel viral disease owing to their immunomodulatory, anti-inflammatory, tissue repair and regeneration characteristics, however, the exact processes are unknown. MSC therapy was found to be effective in lowering immune system overactivation and increasing endogenous healing after SARS-CoV-2 infection by improving the pulmonary microenvironment. Many studies on mesenchymal stem cells have been undertaken concurrently, and we may help speed up the effectiveness of these studies by collecting and statistically analyzing data from them. Based on clinical trial information found on clinicaltrials. gov and on 16 November 2020, which includes 63 clinical trials in the field of patient treatment with COVID-19 using MSCs, according to the trend of increasing studies in this field, and with the help of meta-analysis studies, it is possible to hope that the promise of MSCs will one day be realized. The potential therapeutic applications of MSCs for COVID-19 are investigated in this study.

Keywords: Cell therapy; Clinical Trials; Covid-19; Mesenchymal Stem Cell (MSCs); Regenerative Medicine; SARS-CoV-2.